China National Accord Medicines Corporation Ltd.
Semi-Annual Report 2021
August 2021
Section I. Important Notice, Contents and Interpretation
Board of Directors, Supervisory Committee, all directors, supervisors and senior
executives of China National Accord Medicines Corporation Ltd. (hereinafter
referred to as the Company) hereby confirm that there are no any fictitious
statements, misleading statements, or important omissions carried in this report,
and shall take all responsibilities, individual and/or joint, for the reality,
accuracy and completion of the whole contents.
Lin Zhaoxiong, Principal of the Company, Gu Guolin, person in charger of
accounting works and Wang Ying, person in charge of accounting organ
(accounting principal) hereby confirm that the Financial Report of Semi-
Annual Report 2021 is authentic, accurate and complete.
All directors are attended the Board Meeting for report deliberation.
The Company plans not to pay cash dividends, bonus and carry out capitalizing
of common reserves.
Contents
Section I Importan Notice, Contents and Interpretation...... 2
Section II Company Profile and Main Financial Indexes......6
Section III Management Discussion and Aanalysis......9
Section IV Corporate Governance......31
Section V Enviornmental and Social Responsibility......33
Section VI Important Events......37
Section VII Changes in Shares and Particular about Shareholders......70
Section VIII Preferred Stock...... 76
Section IX Corporate Bonds......77
Section X Financial Report......78
DocumentsAvailable for Reference
I.The financial statements carried with the signature and seals of legal representative, person in charger of accounting works and
person in charge of accounting organ;
II.Original text of all documents of the Company as well as the manuscript of the announcement disclosed in the reporting period on
Juchao Website.
III. Text of the Semi-Annual Report 2021 bearing the signature of the legal representative.
Interpretation
Items Refers to Contents
Listed Company, Company, the Company, Refers to China National Accord Medicines Corporation Ltd.
SinopharmAccord, the Group
SINOPHARM Refers to China National Accord Medicines Corporation Ltd.
Sinopharm Holding Refers to Sinopharm Group Co., Ltd, Controlling shareholder of the
Company
Company Law Refers to Company Law of the People’s Republic of China
Securities Law Refers to Securities Law of the People’s Republic of China
Yuan, 10 thousand Yuan, 100 million Yuan Refers to RMB, RMB 10 thousand, RMB 100 million
Terminology: Refers to
SPD hospital logistics supply chain extension business, IVD
4D business Refers to diagnostic reagent business, CSSD disinfection service, and MWD
equipment life cycle management business
GPO Refers to Group purchasing organizations
Abbreviation: Refers to
Sinopharm Holding Guangzhou Refers to Sinopharm Holding Guangzhou Co., Ltd.
Guoda Drugstore Refers to Sinopharm Holding Guoda Drugstore Co., Ltd.
Sinopharm Holding Guangxi Refers to Sinopharm Holding Guangxi Co., Ltd.
China National Zhijun Refers to China National Zhijun (Shenzhen) Pharmaceutical Co., Ltd.
Zhijun Pharmacy Trade Refers to Shenzhen Zhijun Pharmacy Trade Co., Ltd.
Zhijun Pingshan Refers to China National Zhijun (Shenzhen) Pingshan Pharmaceutical Co.,
Ltd.
Main Luck Pharmaceuticals Refers to Shenzhen Main Luck Pharmaceuticals Inc.
Section II Company Profile and Main Financial Indexes
I. Company profile
Short form of the stock SinopharmAccord,Accord B Stock code 000028, 200028
Stock exchange for listing Shenzhen Stock Exchange
Name of the Company (in
Chinese) 国药集团一致药业股份有限公司
Short form of the Company
(in Chinese if applicable) 国药一致
Foreign name of the Company
(if applicable) China NationalAccord Medicines Corporation Ltd.
Short form of foreign name of
the Company (if applicable) SinopharmAccord
Legal representative Lin Zhaoxiong
II. Person/Way to contact
Secretary of the Board
Name Chen Changbing
Contact add. Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District,
Shenzhen, Guangdong Province
Tel. +(86)75
查看PDF原文
